Physician profile
Millin C Budev
NPI 1073562492
$16,130.61
in general payments reported to CMS, 2019-2025
39 companies · $3,343 in 2025
The $3,343 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,353 · 2020: $1,159 · 2021: $1,413 · 2022: $1,839 · 2023: $1,135 · 2024: $2,889 · 2025: $3,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,366.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,922.63 | 2019-2025 | Clareon, Rocklatan, Lensx |
| Glaukos Corporation | $2,098.43 | 2019-2025 | Idosetr, Idose |
| Harrow Eye, LLC | $1,113.50 | 2024-2025 | Vevye, Iheezo |
| Sight Sciences, INC. | $1,029.35 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $863.53 | 2019-2024 | Clearpath, Streamline, Kahook Dual Blade |
| Bausch & Lomb Americas INC. | $851.48 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $665.92 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $627.60 | 2019-2025 | Cequa |
| Abbvie INC. | $524.74 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Biotissue Holdings INC. | $484.79 | 2019-2025 | |
| Ocular Therapeutix, INC. | $451.88 | 2019-2023 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $443.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $431.99 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $426.34 | 2019-2025 | Tecnis Iol |
| Allergan, INC. | $358.70 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $292.04 | 2019-2021 | |
| Rxsight INC | $219.42 | 2022-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Omeros Corporation | $189.43 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $159.00 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $150.43 | 2022-2024 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $116.77 | 2022-2024 | Omidria, Rayone Spheric, Rayone Aspheric |
| Topcon Healthcare, INC. | $84.49 | 2025 | |
| Dompe US, INC. | $81.56 | 2019-2025 | Oxervate |
| Akorn, INC. | $67.13 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $59.56 | 2022 | |
| Genentech, INC. | $53.24 | 2021 | |
| Iridex Corporation | $50.53 | 2019-2024 | |
| Shire North American Group INC | $47.83 | 2019 | |
| Amgen INC. | $45.32 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $42.50 | 2019 | |
| Apellis Pharmaceuticals, INC. | $26.01 | 2025 | Syfovre |
| Dutch Ophthalmic, USA | $25.13 | 2024 | Tissueblue, Eva, Combined Machine |
| Thea Pharma INC. | $24.50 | 2024 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $23.03 | 2025 | Acthar |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ivantis, INC | $16.27 | 2020 | |
| Eyepoint US, INC. | $15.58 | 2020 | |
| Spinal Simplicity, LLC | $13.53 | 2023 | Ha Minuteman G3-R |
| Merz Pharmaceuticals, LLC | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millin Budev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.